ConductScience.org, home

Paper38020299

Immunohistochemical expression of TROP‑2 (TACSTD2) on the urothelial carcinoma of the urinary bladder and other types of cancer.

Abbas M and 7 others. Oncol Lett, 2023. Cited by 21 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. Immunohistochemical expression of TROP‑2 (TACSTD2) on the urothelial carcinoma of the urinary bladder and other types of cancer. Papers, record 38020299. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/38020299

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Immunohistochemical expression of TROP‑2 (TACSTD2) on the urothelial carcinoma of the urinary bladder and other types of cancer.
PubMed
Journal
Oncol Lett
PubMed
Year
2023
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
21
iCite
Relative citation ratio, by iCite
1.65
iCite
Revised in PubMed
2023-12-01
PubMed

Authors8

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Abbas MMahmoud
2Heitplatz BBarbara
3Bernemann CChristof
4Boegemann MMartin
5Trautmann MMarcel
6Schrader AJAndres Jan
7Wardelmann EEva
8Schlack KKatrin

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References30

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
121551320Expression of Trop2 cell surface glycoprotein in normal and tumor tissues: potential implications as a cancer therapeutic target.J Histochem Cytochem2011https://conductscience.org/library/papers/21551320PubMed
228938585The trophoblast cell surface antigen 2 and miR-125b axis in urothelial bladder cancer.Oncotarget2017https://conductscience.org/library/papers/28938585PubMed
328131785Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial.Lancet Oncol2017https://conductscience.org/library/papers/28131785PubMed
431340094Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma.N Engl J Med2019https://conductscience.org/library/papers/31340094PubMed
524382958Pathologic Response Rates of Gemcitabine/Cisplatin versus Methotrexate/Vinblastine/Adriamycin/Cisplatin Neoadjuvant Chemotherapy for Muscle Invasive Urothelial Bladder Cancer.Adv Urol2013https://conductscience.org/library/papers/24382958PubMed
635118443Organ-specific Adverse Events of Immune Checkpoint Inhibitor Therapy, with Special Reference to Endocrinopathies.touchREV Endocrinol2021https://conductscience.org/library/papers/35118443PubMed
723070813Regulated proteolysis of Trop2 drives epithelial hyperplasia and stem cell self-renewal via β-catenin signaling.Genes Dev2012https://conductscience.org/library/papers/23070813PubMed
827939400Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial.Lancet2017https://conductscience.org/library/papers/27939400PubMed
926952546Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial.Lancet2016https://conductscience.org/library/papers/26952546PubMed
1027269937Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer.J Clin Oncol2016https://conductscience.org/library/papers/27269937PubMed
1128709407Trop2 enhances invasion of thyroid cancer by inducing MMP2 through ERK and JNK pathways.BMC Cancer2017https://conductscience.org/library/papers/28709407PubMed
1234768978Evaluation of Therapeutic Targets in Histological Subtypes of Bladder Cancer.Int J Mol Sci2021https://conductscience.org/library/papers/34768978PubMed
1329989029The emergence of trophoblast cell-surface antigen 2 (TROP-2) as a novel cancer target.Oncotarget2018https://conductscience.org/library/papers/29989029PubMed
1424086649Overexpression of TROP2 predicts poor prognosis of patients with cervical cancer and promotes the proliferation and invasion of cervical cancer cells by regulating ERK signaling pathway.PLoS One2013https://conductscience.org/library/papers/24086649PubMed
1532183076Epidemiology of Bladder Cancer.Med Sci (Basel)2020https://conductscience.org/library/papers/32183076PubMed
1633577729Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma.N Engl J Med2021https://conductscience.org/library/papers/33577729PubMed
1735477165Trophoblast Cell Surface Antigen 2 Expression in Human Tumors: A Tissue Microarray Study on 18,563 Tumors.Pathobiology2022https://conductscience.org/library/papers/35477165PubMed
1828967485First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study.Lancet Oncol2017https://conductscience.org/library/papers/28967485PubMed
1929901071Curcumin inhibits cell proliferation and motility via suppression of TROP2 in bladder cancer cells.Int J Oncol2018https://conductscience.org/library/papers/29901071PubMed
2035735421Trop-2 in Upper Tract Urothelial Carcinoma.Curr Oncol2022https://conductscience.org/library/papers/35735421PubMed

See all 30 referencesDownload CSV of references

Cited by17

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 21 citations.

PMIDTitleJournalYearIn PapersSource
42729864Structure and function of therapeutic antibodies approved by the US FDA in 2025.Antib Ther2026https://conductscience.org/library/papers/42729864PubMed
42729159Disease stage-dependent expression of ADC-related biomarkers in urothelial carcinoma.Transl Androl Urol2026https://conductscience.org/library/papers/42729159PubMed
42665429TROP2 Expression in Bladder Transurethral Resection Specimens: Correlation With Histological Grade and Survival.In Vivo2026https://conductscience.org/library/papers/42665429PubMed
42137465SOX2-positive upper tract urothelial carcinoma: Clinicopathological characteristics and therapeutic implications.Oncol Lett2026https://conductscience.org/library/papers/42137465PubMed
41680099Expression of Nectin-4 and Trop-2 in upper tract urothelial carcinoma: implications for biomarker-driven antibody-drug conjugate therapy.J Pathol Clin Res2026https://conductscience.org/library/papers/41680099PubMed
41652619The emerging role of TROP2 as a diagnostic and prognostic biomarker in bladder tumor.Cancer Cell Int2026https://conductscience.org/library/papers/41652619PubMed
41409251Overcoming resistance in advanced urothelial carcinoma: mechanisms of escape from antibody-drug conjugates and FGFR3 inhibition.Front Oncol2025https://conductscience.org/library/papers/41409251PubMed
40931013Modulating the PPARγ pathway upregulates NECTIN4 and enhances chimeric antigen receptor (CAR) T cell therapy in bladder cancer.Nat Commun2025https://conductscience.org/library/papers/40931013PubMed
40688535TROP2-targeted molecular imaging: a promising tool for precision oncology.Am J Nucl Med Mol Imaging2025https://conductscience.org/library/papers/40688535PubMed
40688533[89Zr]Zr-DFO-Trodelvy immunoPET for noninvasive Trop2 imaging in bladder cancer.Am J Nucl Med Mol Imaging2025https://conductscience.org/library/papers/40688533PubMed
40591027Neoadjuvant treatment patterns and biomarker selection in muscle-invasive bladder cancer.Discov Oncol2025https://conductscience.org/library/papers/40591027PubMed
40526099Optimizing enfortumab vedotin plus pembrolizumab therapy.Oncotarget2025https://conductscience.org/library/papers/40526099PubMed
40316856Integrating analysis of multi-omics summary data identifies novel plasma protein biomarkers and drug targets for bladder cancer.Discov Oncol2025https://conductscience.org/library/papers/40316856PubMed
40059341ImmunoPET Imaging of Trop2 Expression in Bladder Cancer Using [64Cu]Cu-NOTA-Trodelvy.Mol Pharm2025https://conductscience.org/library/papers/40059341PubMed
39835546Exploring the Therapeutic Potential of TROP2 Gene Silencing in Hepatocellular Carcinoma.Recent Pat Biotechnol2026https://conductscience.org/library/papers/39835546PubMed
39705501Trop-2 and Ephrin B2 expression in urothelial carcinoma with divergent differentiation and aggressive urothelial carcinoma subtypes.Am J Clin Pathol2025https://conductscience.org/library/papers/39705501PubMed
39280671Are primary tumors suitable for biomarker-guided treatment of metastatic urothelial cancer?Transl Androl Urol2024https://conductscience.org/library/papers/39280671PubMed

Download CSV of cited by

Genes8

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
CD27429126PubTator's text mininghttps://conductscience.org/library/genes/29126NCBI Gene
CTNNB11499PubTator's text mininghttps://conductscience.org/library/genes/1499NCBI Gene
FGFR32261PubTator's text mininghttps://conductscience.org/library/genes/2261NCBI Gene
MAPK15594PubTator's text mininghttps://conductscience.org/library/genes/5594NCBI Gene
MAPK85599PubTator's text mininghttps://conductscience.org/library/genes/5599NCBI Gene
NECTIN481607PubTator's text mininghttps://conductscience.org/library/genes/81607NCBI Gene
PDCD15133PubTator's text mininghttps://conductscience.org/library/genes/5133NCBI Gene
TACSTD24070PubTator's text mininghttps://conductscience.org/library/genes/4070NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/38020299

GET https://conductscience.org/api/papers/v1/38020299/references?page=2